GLP-1 drugs reduce diabetic retinopathy risk by 69% and treatment-requiring eye disease by 82% over 10 years | Research

The takeaway

Over 10-year follow-up, GLP-1 RA users had 69% lower risk of diabetic retinopathy (HR 0.31), 60% lower DME risk (HR 0.40), and 82% lower treatment-requiring DR/DME risk (HR 0.18), after adjusting for HbA1c and its longitudinal changes.

82% less eye treatment needed
GLP-1 drugs reduced treatment-requiring diabetic eye disease by 82% over 10 years after accounting for HbA1c changes—resolving the retinopathy safety controversy

What the researchers found

DR: HR 0.31 (0.26-0.37, p<0.001). DME: HR 0.40 (0.27-0.59, p<0.001). Treatment-requiring DR/DME: HR 0.18 (0.08-0.40, p<0.001). 10-year follow-up. Adjusted for longitudinal HbA1c changes.

Why it matters

This is the strongest evidence yet that GLP-1 drugs protect against diabetic eye disease—accounting for the HbA1c change confounder that has plagued prior studies. An 82% reduction in treatment-requiring disease is clinically transformative.

How the study worked

Longitudinal retrospective cohort. 10-year follow-up from T2DM diagnosis. Cox regression adjusted for 10+ variables including longitudinal HbA1c change. Survival analyses.

What this study cannot tell us

Retrospective. Cannot fully exclude confounding. GLP-1 users may differ from non-users. Specific GLP-1 drugs not compared. "GLP-1 RA use" definition may vary.

How to read the evidence

Large longitudinal cohort with 10-year follow-up and comprehensive adjustment including longitudinal HbA1c. Strong observational evidence.

When this study was published

Published in 2025.

The bigger picture

This resolves the GLP-1 retinopathy controversy: prior studies suggested increased risk from rapid glucose improvement. By adjusting for HbA1c changes, this study reveals the underlying protective effect—GLP-1 drugs dramatically reduce eye disease risk.

Questions still open

Should GLP-1 drugs be preferred for diabetics at high retinopathy risk?
Is the protection from direct retinal effects or metabolic improvement?
Do all GLP-1 drugs provide equal eye protection?

Common questions

Do GLP-1 drugs protect eyesight in diabetes?

Strong evidence says yes. This 10-year study found GLP-1 drug users had 69% less diabetic retinopathy, 60% less macular edema, and 82% less treatment-requiring eye disease. Importantly, this was after accounting for blood sugar changes—addressing concerns from earlier studies that suggested GLP-1 drugs might worsen eye disease.

I heard GLP-1 drugs can cause eye problems—is that true?

Earlier studies raised concerns, but this research shows those concerns were likely due to rapid blood sugar improvement (which temporarily worsens retinopathy) rather than the drug itself. After properly adjusting for blood sugar changes over 10 years, GLP-1 drugs were strongly protective against all forms of diabetic eye disease.

Read the original research

Real-world Associations Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Accounting for Longitudinal Glycemic Control.

Retina (Philadelphia, Pa.)

View on PubMed ↗Publisher’s paper ↗

Citation

Talebi, Ramin; Fortes, Blake H; Yu, Fei; Coleman, Anne L; Tsui, Irena. (2025). Real-world Associations Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Accounting for Longitudinal Glycemic Control.. Retina (Philadelphia, Pa.). https://doi.org/10.1097/IAE.0000000000004507